Benzinga · Feb 12, 2026
NB
NASDAQ · NBY
NovaBay Pharmaceuticals, Inc.
Healthcare · Biotechnology
$1.95
Down-$0.48 (-24.62%)
Updated Aug 23, 2026, 7:58 PM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 17.17M
- P/E ratio
- 5
- Dividend yield
- 41.03%
- 52-week range
- $0.43 – $19.95
- Volume
- 637.6K
- Avg. volume
- 547.34K
Price performance
NBY price history
1M range · 0 trading sessions · Daily adjusted prices
NBY does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest NBY news
The latest Smart Investors Daily articles mentioning NBY.
Stock researchCompany · Overview
NBY research
Overview
Company profile and research snapshot.
Company profile
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 11, 2024 | Ascendiant Capital | Buy | — |
| Aug 11, 2023 | Ladenburg Thalmann | Buy | — |
| May 20, 2022 | Ascendiant Capital | Buy | — |
| Sep 18, 2019 | Ladenburg Thalmann | Buy | — |
| Mar 13, 2019 | H.C. Wainwright | Neutral | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Jan 13, 2026
NovaBay: 'Hold' Rating As New M&A Direction Could Evolve But With Risks
NovaBay Pharmaceuticals is rated 'Hold' after divesting core assets and shifting to a speculative, strategic alternative focus. Read my analysis of NBY stock.
Yahoo · Jan 11, 2026
Assessing NovaBay Pharmaceuticals’ (NBY) Valuation After A Sharp Short Term Share Price Surge
Event context and why NovaBay might be on your radar NovaBay Pharmaceuticals (NBY) has drawn attention recently as investors look at its current pricing and past returns to reassess the risk and potential reward profile of this wound care focused business. See our latest analysis for NovaBay Pharmaceuticals. The recent surge in NovaBay Pharmaceuticals' share price, including a 1 day share price return above 100% and a very large 1 year total shareholder return, follows a period where longer...
feeds.benzinga.com · Dec 4, 2025
Why Did KALA BIO Shares Jump Over 22% After Hours?
KALA BIO shares jumped over 22% after Oxford Finance acquired a 16.5% stake, amid recent leadership changes and continued year-to-date losses.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
